Project: Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity

Acronym RADprecise (Reference Number: ERAPERMED2018-244)
Duration 01/03/2019 - 28/02/2022
Project Topic Aim of this collaborative translational project is to achieve personalized radiotherapy (RT) treatment planning for cancer patients by incorporating into treatment planning systems (TPS) information from predictive models for RT-induced toxicity based on data from biological tests of individual cellular response to irradiation. This combines the (pre-)clinical research (Module 1A/B) with Module 2B “Towards application in health care”. Goal is to tailor RT at the individual patient level by minimizing toxicity while maximizing tumour control. We will use and extend data from a prospective patient cohort established in the REQUITE project (, with 3800 breast and prostate cancer patients and standardized collection of clinical, dosimetric and toxicity data, biobank and a minimum of 2 years follow-up. For RADprecise, biological stratification will be enhanced by newly generated information from ATM nucleoshuttling assay and transcriptomics/microRNA sequence analysis (using available PAXgene tubes). Follow-up of the patient cohort will be extended to 4-5 years to allow scoring of long-term RT-related adverse effects and to collect new blood and skin samples for the nucleoshuttling test. RADprecise will use statistical models and machine learning to integrate the new biological data as well as already available genomics data and functional information from radiation induced lymphocyte apoptosis assay to develop prediction models for RT related adverse effects, which will be validated in an independent sample. Algorithms will be integrated into treatment planning systems for biologically extended TPS. Health economics analyses will be conducted. RADprecise is interdisciplinary, including leading clinical scientists from academia and health research, Small Medium Enterprises as well as patient advocates. Most collaborators have already cooperated on related topics, which provide the basis for RADprecise to take biological optimisation into the clinic.
Network ERA PerMed
Call 1st Joint Transnational Call for Proposals (2018)

Project partner

Number Name Role Country
1 German Cancer Research Center (DKFZ) Coordinator Germany
2 Neolys Diagnostics Partner France
3 Vall d'Hebron Institute of Oncology (VHIO) Partner Spain
4 Fundacion Publica Galega Medicina Xenomica (FPGMX) Partner Spain
5 Fondazione IRCCS Instituto Nazionale dei Tumori (INT) Partner Italy
6 Aquilab Partner France
7 Politecnico di Milano (POLIMI) Partner Italy